IQ-AI Ltd

  • News & Announcements
  • Shareholder Information
  • Investor Relations
  • Significant Shareholders
  • Publications
  • Home
  • Corporate News & Announcements
  • IQ-AI RNS News & Announcements
  • Imaging Biometrics Announces Channel Partnership
 

News

Tuesday, 12 July 2022 / Published in IQ-AI RNS News & Announcements

Imaging Biometrics Announces Channel Partnership

RNS Number : 9294R
IQ-AI Limited
11 July 2022
 

IQ-AI Limited

(“IQ-AI” or the “Company”)

 

Imaging Biometrics Announces Channel Partnership

 

IQ-AI Limited (OTCQB: IQAIF) (LSE: IQAI), is pleased to announce that its medical imaging analysis software, IB Clinic®, is now available via the newly launched Bayer Calantic platform. This latest distribution partnership continues IQ-AI’s strategy of making IB Clinic’s unique quantitative solutions accessible through widespread, global networks and marks the culmination of previously announced integration and validations efforts initiated in 2021.

Artificial intelligence (AI) marketplace platforms provide clinicians with a one-stop-shop for a wide array of medical imaging solutions. These platforms simplify and streamline access to proven tools, allowing clinicians to easily harness the exclusive capabilities that can benefit patients. IQ-AI intends to accelerate adoption of IB Clinic for healthcare providers through these global networks. 

“Whilst it is too soon to predict the revenue impact of this new partnership, we are hopeful that it marks a significant expansion of availability globally,” said Trevor Brown, CEO of IQ-AI.

About IQ-AI Limited

IQ-AI Limited, (LON: IQAI) (OTCQB: IQAIF), the parent company of Wisconsin-based Imaging Biometrics, LLC (IB), is focused on delivering quantitative imaging platforms and therapeutics that transform how clinicians diagnose and treat patients more efficiently and effectively. For more information about Imaging Biometrics, visit the company’s website at www.imagingbiometrics.com

 

The Directors of the Company accept responsibility for the contents of this announcement.

 

-ENDS-

 

For further information, please contact:

 IQ-AI Limited

Trevor Brown/Brett Skelly/Vinod Kaushal

 

Tel: 020 7469 0930

Peterhouse Capital Limited (Financial Adviser and Broker)

Lucy Williams/Heena Karani

Tel: 020 7220 9797

 

About IQ-AI Limited

IQ-AI Limited, (LON: IQAI) (OTCQB: IQAIF), the parent company of Wisconsin-based Imaging Biometrics, LLC (IB), is focused on delivering quantitative imaging platforms and therapeutics that transform how clinicians diagnose and treat patients more efficiently and effectively. For more information about Imaging Biometrics, visit the company’s website at www.imagingbiometrics.com

 

Market Abuse Regulation (MAR) Disclosure

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation EU 596/2014 as it forms part of retained EU law (as defined in the European Union (Withdrawal) Act 2018).

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
Article source

Recent Posts

  • TR1 – Notification of Major Holdings

    RNS Number : 8120U IQ-AI Limited 03 August 2022...
  • Result of AGM

    RNS Number : 2442N IQ-AI Limited 30 May 2022   ...
  • Submission of FDA 510(k) Application for IB Zero G

    RNS Number : 3069N IQ-AI Limited 31 May 2022   ...
  • Notice of AGM

    RNS Number : 4440K IQ-AI Limited 05 May 2022   ...
  • IB Broadens Quantitative Mapping

    RNS Number : 1476K IQ-AI Limited 03 May 2022   ...
Portions copyright © 2010-2022 IQ-AI Ltd. All Rights Reserved.
TOP
Our website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish.AcceptReject
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT